Abstract
Orally disintegrating tablets (ODTs) have emerged as a preferred dosage form due to their ability to rapidly dissolve or disintegrate in the mouth without the need for water. This property enhances patient compliance, especially for those with swallowing difficulties, such as pediatric, geriatric, or dysphagic patients. However, the formulation of ODTs presents several challenges, including ensuring rapid disintegration, maintaining stability, achieving appropriate taste masking, and managing the delicate balance between excipients and active pharmaceutical ingredients. This article discusses the various hurdles encountered during the formulation of ODTs and explores strategies to overcome them, focusing on the formulation components, manufacturing processes, and clinical considerations.
All articles published in the American Journal of Pharmaceutics are open access and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows users to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given, a link to the license must be provided, and any changes must be indicated.
-
Authors retain full copyright of their work.
-
The journal does not restrict reuse of content, provided proper citation of the original publication is made.